Valuation: Roche Holding AG

Market Cap 284B 349B 302B 258B 485B 33,419B 493B 3,324B 1,299B 16,735B 1,312B 1,284B 55,613B P/E 2026 *
19.8x
P/E 2027 * 17.6x
Enterprise Value 295B 363B 313B 268B 504B 34,699B 512B 3,451B 1,349B 17,376B 1,362B 1,333B 57,743B EV / Sales 2026 *
4.7x
EV / Sales 2027 * 4.39x
Free-Float
88.78%
Yield 2026 *
2.81%
Yield 2027 * 2.88%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 349B
-2.25%-0.47%+68.30%+115.90% 1,052B
-0.66%+0.43%+47.39%+50.54% 627B
-0.54%+1.39%+20.69%+63.99% 441B
-1.99%-3.32%+38.71%+35.41% 349B
-1.05%-2.81%+23.07%+35.70% 287B
-2.12%-3.67%-1.14%+5.37% 241B
-0.63%+1.04%+40.05%+56.09% 224B
-1.19%-3.41%-9.57%-52.71% 202B
+0.16%+3.87%+16.89%+73.73% 172B
Average -1.16%+0.43%+27.15%+42.67% 399.46B
Weighted average by Cap. -1.36%+0.32%+39.09%+61.29%

Financials

2026 *2027 *
Net sales 62.64B 77.19B 66.67B 56.97B 107B 7,381B 109B 734B 287B 3,696B 290B 284B 12,282B 65.47B 80.67B 69.67B 59.54B 112B 7,714B 114B 767B 300B 3,863B 303B 296B 12,837B
Net income 14.51B 17.87B 15.44B 13.19B 24.8B 1,709B 25.21B 170B 66.46B 856B 67.11B 65.65B 2,844B 16.33B 20.12B 17.38B 14.85B 27.93B 1,924B 28.39B 191B 74.82B 964B 75.55B 73.91B 3,202B
Net Debt 10.87B 13.39B 11.56B 9.88B 18.58B 1,280B 18.89B 127B 49.78B 641B 50.27B 49.18B 2,131B 4.02B 4.95B 4.28B 3.66B 6.87B 474B 6.99B 47.1B 18.41B 237B 18.59B 18.19B 788B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA